Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Providers and patients must navigate which benefit a therapy will fall under
At the time of study start (July 2023), the only available RCT evidence demonstrated a reduction in alcohol intake in response to GLP-1RAs only in people with obesity, so we focused our study on that population 19
El-Ouaghlidi, A
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
& Mortensen, P
US$ 22.59
US$ 25.11
US$ 23.99
US$ 21.20
US$ 23.56
US$ 26.81
